Abstract
The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.
Original language | English |
---|---|
Patent number | WO2016102680 |
Priority date | 23/12/2014 |
Publication status | Published - 30-Jun-2016 |